Canertinib pfizer

IDrugs. 2004 Jan;7(1):58-63.

Abstract

Canertinib, a water-soluble, orally available analog of PD-169414 (Pfizer Inc), is an EGFR tyrosine kinase inhibitor under development by Pfizer Inc as a potential treatment for cancer.

Publication types

  • Review

MeSH terms

  • Angiogenesis Inhibitors / adverse effects
  • Angiogenesis Inhibitors / pharmacokinetics
  • Angiogenesis Inhibitors / therapeutic use*
  • Angiogenesis Inhibitors / toxicity
  • Animals
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / pharmacokinetics
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Agents / toxicity
  • Clinical Trials, Phase I as Topic*
  • Humans
  • Morpholines / adverse effects
  • Morpholines / pharmacokinetics
  • Morpholines / therapeutic use*
  • Morpholines / toxicity
  • Neoplasms / drug therapy*
  • Structure-Activity Relationship

Substances

  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Morpholines
  • Canertinib